Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Èíôîðìàöèÿ è êîììåð÷åñêàÿ ðåêëàìà > Áèîëîãè÷åñêè àêòèâíûå äîáàâêè (ÁÀÄ)

Áèîëîãè÷åñêè àêòèâíûå äîáàâêè (ÁÀÄ) Ðàçìåùåíèå ðåêëàìû ïëàòíîå. Ïèøèòå.

Çàêðûòàÿ òåìà
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 25.04.2015, 17:23
tishaa tishaa âíå ôîðóìà Ïîë æåíñêèé
çàáàíåí
 
Ðåãèñòðàöèÿ: 11.01.2010
Ãîðîä: Êèåâ
Ñîîáùåíèé: 391
Ñêàçàë(à) ñïàñèáî: 114
Ïîáëàãîäàðèëè 2 ðàç(à) çà 2 ñîîáùåíèé
tishaa *
Õðàíåíèå Îìåãà-3

Çäðàâñòâóéòå. Êóïèëà ïàðó íåäåëü íàçàä áàíêó Îìåãà-3 â êàïñóëàõ. Íî ïî íåçíàíèþ õðàíèëà íå â õîëîäèëüíèêå.
1. Ìîæíî ëè ýòó îìåãó óïîòðåáëÿòü èëè ýòî óæå îïàñíî? Ìîæíî ëè äàâàòü ðåáåíêó?
2. Â÷åðà äàëà îäíó êàïñóëó ðåáåíêó 5 ëåò, îíà ðàñêóñèëà, íî âûïëþíóëà, ãëîòàòü íå ñòàëà. Íå ïðèíåñåò ëè ýòî âðåäà?
  #2  
Ñòàðûé 25.04.2015, 17:26
Àâàòàð äëÿ doctor101
doctor101 doctor101 âíå ôîðóìà
ÂÐÀ× êîíñóëüòàíò
      
 
Ðåãèñòðàöèÿ: 24.07.2004
Ãîðîä: ISRAEL.HAIFA
Ñîîáùåíèé: 19,723
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 4,535 ðàç(à) çà 4,418 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 1
doctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådoctor101 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ïîñêîëüêó áàäû íå ÿâëÿþòñÿ ëå÷åáíûìè ïðåïàðàòàìè-âñå ïî âàøåìó óñìîòðåíèþ
Ðåáåíîê óìíåå-âûïëåâûâàåò
__________________
doctor Ðolonsky
israel
Ñíèìêè ñìîòðþ òîëüêî â ïðÿìîì ïîêàçå.,áåç íåîáõîäèìîñòè ñêà÷èâàíèÿ.
Ïðîñüáà ïîêàçûâàòü ñíèìêè â ïðàâèëüíîì ïîëîæåíèè.
  #3  
Ñòàðûé 09.05.2015, 04:08
sergiys sergiys âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.04.2015
Ãîðîä: Êèåâ
Ñîîáùåíèé: 11
Ñêàçàë(à) ñïàñèáî: 1
sergiys *
ß ïðîøó ïðîùåíèÿ, íî ñ ÷åãî Âû âçÿëè, ÷òî Omega-3 â êàïñóëàõ äîëæíà õðàíèòñÿ â õîëîäèëüíèêå? Ó ìåíÿ îíà ïî ïîë ãîäà-ãîä ñòîèò ïðè êîìíàòíîé òåìïåðàòóðå è âðîäå íè÷åãî ñòðàøíîãî íå ïðîèçîøëî. Ñåé÷àñ ñïåöèàëüíî ïîñìîòðåë íà áàíêó è íå óâèäåë íè ñëîâà î êàêèõ ëèáî ñïåöèàëüíûõ óñëîâèÿõ õðàíåíèÿ.
Ê òîìó æå, ïîñëåäíèé ðàç Omega-3 ÿ ïîêóïàë çàãðàíèöåé è òàì â àïòåêå îíà ñòîÿëà íà îáû÷íîé âèòðèíå.

Ï.Ñ. Ïðîøó ïðîùåíèÿ ó àäìèíèñòðàöèè, åñëè â ýòîì ðàçäåëå èìåþò ïðàâî îòâå÷àòü òîëüêî âðà÷è. Çàõîäèë â ïðàâèëà è íå íàøåë òàì íè ñëîâà î çàïðåòå ïîëüçîâàòåëÿì îñòàâëÿòü ñîîáùåíèÿ â ýòîì ðàçäåëå.
  #4  
Ñòàðûé 21.05.2015, 23:21
Íåññè Íåññè âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 09.04.2006
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 192
Ñêàçàë(à) ñïàñèáî: 75
Íåññè *
Íà íàøåì ðóññêîì ðûáüåì æèðå íàïèñàíî, ÷òî õðàíèòü â õîëîäèëüíèêå, íà àìåðèêàíñêîì ïîñëå âñêðûòèÿ...
  #5  
Ñòàðûé 28.09.2016, 21:37
DrGreen1 DrGreen1 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 28.09.2016
Ãîðîä: Mtl, Canada
Ñîîáùåíèé: 41
Ïîáëàãîäàðèëè 14 ðàç(à) çà 14 ñîîáùåíèé
DrGreen1 *
Öèòàòà:
Ñîîáùåíèå îò doctor101 Ïîñìîòðåòü ñîîáùåíèå
ïîñêîëüêó áàäû íå ÿâëÿþòñÿ ëå÷åáíûìè ïðåïàðàòàìè-âñå ïî âàøåìó óñìîòðåíèþ
Ðåáåíîê óìíåå-âûïëåâûâàåò
Î÷åíü çàäåë âàø ñàðêàçì ïî ïîâîäó Îìåãà-3 æèðîâ. ß ïîëàãàþ, ýòî ïðîäèêòîâàíî îòñóòñòâèåì çíàíèé â ýòîé îáëàñòè.
Íåëüçÿ íåäîîöåíèâàòü èõ ðîëü â ìåòàáîëèçìå ÷åëîâåêà.
  #6  
Ñòàðûé 28.09.2016, 21:45
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,706
Ïîáëàãîäàðèëè 33,384 ðàç(à) çà 31,729 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Àíàòîëèé,
Óáåäèòåëüíàÿ ïðîñüáà íå íà÷èíàòü ñâîþ äåÿòåëüíîñòü íà ôîðóìå ñ Âàøèõ äîãàäîê ïî ïîâîäó óðîâíÿ îáðàçîâàíèÿ êîëëåã-êîíñóëüòàíòîâ. Íà÷íèòå ñ ïåðå÷èñëåíèÿ äèàãíîçîâ/áîëåçíåé, êîãäà ðåáåíêó ïîêàçàíî (ñ ëå÷åáíîé èëè ïðîô. öåëüþ) íàçíà÷åíèÿ îìåãà-3 ÏÆÊ, ñîãëàñíî êàíîíàì äîêàçàòåëüíîé ìåäèöèíû èëè ïîçèöèè ïåäèàòðîâ Êàíàäû. Ìîäåðàòîð
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
  #7  
Ñòàðûé 30.09.2016, 20:25
DrGreen1 DrGreen1 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 28.09.2016
Ãîðîä: Mtl, Canada
Ñîîáùåíèé: 41
Ïîáëàãîäàðèëè 14 ðàç(à) çà 14 ñîîáùåíèé
DrGreen1 *
Öèòàòà:
Ñîîáùåíèå îò Dr.Vad Ïîñìîòðåòü ñîîáùåíèå
Óâàæàåìûé Àíàòîëèé,
Óáåäèòåëüíàÿ ïðîñüáà íå íà÷èíàòü ñâîþ äåÿòåëüíîñòü íà ôîðóìå ñ Âàøèõ äîãàäîê ïî ïîâîäó óðîâíÿ îáðàçîâàíèÿ êîëëåã-êîíñóëüòàíòîâ. Íà÷íèòå ñ ïåðå÷èñëåíèÿ äèàãíîçîâ/áîëåçíåé, êîãäà ðåáåíêó ïîêàçàíî (ñ ëå÷åáíîé èëè ïðîô. öåëüþ) íàçíà÷åíèÿ îìåãà-3 ÏÆÊ, ñîãëàñíî êàíîíàì äîêàçàòåëüíîé ìåäèöèíû èëè ïîçèöèè ïåäèàòðîâ Êàíàäû. Ìîäåðàòîð
Ñîððè. Íè÷åãî ëè÷íîãî.
Íå áóäó äîëãî è ñëèøêîì ïîäðîáíî ïèñàòü î ëèïèäíîì ñèíòåçå, åãî ìåòàáîëèçìå, äàáû íå îñêîðáëÿòü êîëëåã î÷åâèäíûìè äàííûìè, ñêàæó òàê, ÷òî ïî ìîåìó ñêðîìíîìó ìíåíèþ è ìíåíèþ ìíîãèõ íàøèõ ñïåöèàëèñòîâ: ñåìåéñòâî ëèïèäîâ îìåãà 3 (Ñ18:3) óñïåøíî çàìåùàåò àðàõèäîíîâóþ êèñëîòó â ìåìáðàíàõ òðîìáîöèòîâ è ñíèæàåò ïðîäóêöèþ òðîìáîêñàíà è òåíäåíöèþ òðîìáîöèòîâ ê àããðåãàöèè. Ïîñòóïëåíèå ïèùè áîãàòîé îìåãà-3 òàêæå ìîæåò ñïîñîáñòâîâàòü ñíèæåíèþ òðèãëèöåðèäîâ â ñûâîðîòêè êðîâè. ß êîíå÷íî íå ãîâîðþ óæå î ôàêòå, ÷òî ïîëèíåíàñûùåííûå æèðíûå êèñëîòû(â òîì ÷èñëå ëèíîëåíîâàÿ êèñëîòà èç ñåìåéñòâà îìåãà3) âëèÿþò íà òàêóþ ôóíêöèþ êàê ïðîíèöàåìîñòü ìåìáðàíû êëåòêè, áåç êîòîðîé, êàê íàì âñåì êîíå÷íî æå èçâåñòíî, ðèñê âîçíèêíîâåíèÿ àòåðîñêëåðîçà âîçðàñòàåò.
Øàíà Òîâà âå Ìåòóêà, äîðîãîé êîëëåãà!
  #8  
Ñòàðûé 05.10.2016, 03:04
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,706
Ïîáëàãîäàðèëè 33,384 ðàç(à) çà 31,729 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñïàñèáî, êîëëåãà, è Âàñ ñ ïðàçäíèêîì! Ðå÷ü íå î âàæíîñòè òåõ èëè èíûõ íóòðèåíòîâ â ìåòàáîëèçìå, à êîãäà ïðè êàêîì äèàãíîçå Âû êàê âðà÷ ïðèåìíîãî ïîêîÿ íàçíà÷èòå ðåáåíêó èìåííî îìåãà3 ñ ëå÷åáíîé öåëüþ?
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
  #9  
Ñòàðûé 05.10.2016, 18:51
DrGreen1 DrGreen1 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 28.09.2016
Ãîðîä: Mtl, Canada
Ñîîáùåíèé: 41
Ïîáëàãîäàðèëè 14 ðàç(à) çà 14 ñîîáùåíèé
DrGreen1 *
Öèòàòà:
Ñîîáùåíèå îò Dr.Vad Ïîñìîòðåòü ñîîáùåíèå
Ñïàñèáî, êîëëåãà, è Âàñ ñ ïðàçäíèêîì! Ðå÷ü íå î âàæíîñòè òåõ èëè èíûõ íóòðèåíòîâ â ìåòàáîëèçìå, à êîãäà ïðè êàêîì äèàãíîçå Âû êàê âðà÷ ïðèåìíîãî ïîêîÿ íàçíà÷èòå ðåáåíêó èìåííî îìåãà3 ñ ëå÷åáíîé öåëüþ?
Îê, ÿ ïîíèìàþ ê ÷åìó âû êëîíèòå.
1-å Ïðè òåõ æå ðàâíûõ óñëîâèÿõ êàê è âû, âðà÷ ãåìàòîëîã, áóäåòå íàçíà÷àòü âèòàìèíû. ß íàñòîÿòåëüíî ðåêîìåíäóþ áîëåå âíèìàòåëüíî èçó÷èòü ñâîéñòâà äàííûõ ÆÊ, ïðèâåäåííûõ ìíîþ. Åñòü ðÿä çàáîëåâàíèé(äèàáåò, íàñëåäñòâåííûå äåôåêòû ýíçèìîâ, ïîâûøåííûé ðèñê àòåðîñêëåðîçà, ãèïåðëèïèäåìèè è ò.ä.) ïðè êîòîðûõ, èìååò ìåñòî îáÿçàòåëüíîå íàçíà÷åíèå, à çíàÿ îñíîâû ëèïèäíîãî ìåòàáîëèçìà áóäåò íå ñëîæíî îïðåäåëèòüñÿ ñ àëãîðèòìîì íàçíà÷åíèÿ äàííîãî ïðåïàðàòà, äàæå íå ïðîôèëüíîìó ñïåöèàëèñòó. ÍÎ ýòî íå îáÿçàòåëüíûå óñëîâèÿ äëÿ íàçíà÷åíèÿ, ÿ äóìàþ âû ïîíèìàåòå?!
2-å Ìîé ïîèíò áûë â òîì, ÷òî íå óìåñòíûé ñàðêàçì â ñòîðîíó ðîäèòåëÿ êîòîðûé çàáîòèòüñÿ î çäîðîâüå ðåáåíêà.
3-å Èñõîäÿ èç ëîãèêè êîëëåãè, òî åñëè ðåáåíîê ëþáèò ïåïñè, ÷èïñû è òîííû øîêîëàäà òî ýòî áîëåå ïîëåçíî?! Äåòè âîîáùå ðåäêî îòäàþò ïðåäïî÷òåíèå ïîëåçíûì âåùàì.

ß î÷åíü ïîëüùåí, ÷òî âû èìååòå áîëüøîé èíòåðåñ ê ïðîáëåìàì ìåòàáîëèçìà ëèïèäîâ. Åñëè ÷òî îáðàùàéòåñü çà êîíñóëüòàöèåé, âñåãäà ðàä áóäó îòâåòèòü.
  #10  
Ñòàðûé 05.10.2016, 21:12
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,706
Ïîáëàãîäàðèëè 33,384 ðàç(à) çà 31,729 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âñÿ èíôà óæå äàâíî èçëîæåíà â ìåä. ïåðèîäèêå - âñå íà óðîâíå ãèïîòåç, íåò íèêàêîé íóæäû "èçó÷àòü ñâîéñòâà äàííûõ ÆÊ, ïðèâåäåííûõ" êåì-ëèáî:

Prostaglandins Other Lipid Mediat. 2015 Jul;120:72-9.
Beneficial effects of ω-3 PUFA in children on cardiovascular risk factors during childhood and adolescence.
Bonafini S1, Antoniazzi F2, Maffeis C2, Minuz P3, Fava C3.

Omega-3 polyunsatured fatty acids (ω-3 PUFA) are essential nutrients mainly derived from fish and seafood but present also in vegetables such as nuts and seed-oils. Some epidemiological and clinical studies indicate a protection of ω-3 FA against cardiovascular disease and a favourable effect on cardiovascular risk factors control in adults. The evidences of their effects in children and adolescents are scanty but a possible beneficial role, especially for insulin sensitivity and blood pressure control, has been proposed. In this review we want to focus especially on the evidences, which could justify the assumption of ω-3 in children and adolescents, and to underline the aspects which need further investigation. Mechanisms through which ω-3 FA act are manifolds and still a matter of investigation: beside their interaction with ion channel and their influence on plasma membrane fluidity, probably the main effect is acting as competitor for cytochrome P-450 (CYP) with respect to ω-6 FA. Thus, they can modulate the biosynthesis of eicosanoids and other lipid mediators, which likely exert a protective action. Another suggestive hypothesis is that their beneficial effect is not dependent only on the intake of ω-3 FA, but also on the complex interaction between different nutrients including ω-3 and other FAs with polymorphisms in genes involved in ω-3 FA modulation. This complex interaction has seldom been explored in children and adolescents. Further studies are needed to investigate all these points in order to find a better collocation of ω-3 FA on the available armamentarium for preventive, possibly individualized, medicine.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
  #11  
Ñòàðûé 06.10.2016, 19:12
DrGreen1 DrGreen1 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 28.09.2016
Ãîðîä: Mtl, Canada
Ñîîáùåíèé: 41
Ïîáëàãîäàðèëè 14 ðàç(à) çà 14 ñîîáùåíèé
DrGreen1 *
Öèòàòà:
Ñîîáùåíèå îò Dr.Vad Ïîñìîòðåòü ñîîáùåíèå
Âñÿ èíôà óæå äàâíî èçëîæåíà â ìåä. ïåðèîäèêå - âñå íà óðîâíå ãèïîòåç, íåò íèêàêîé íóæäû "èçó÷àòü ñâîéñòâà äàííûõ ÆÊ, ïðèâåäåííûõ" êåì-ëèáî:

Prostaglandins Other Lipid Mediat. 2015 Jul;120:72-9.
Beneficial effects of ω-3 PUFA in children on cardiovascular risk factors during childhood and adolescence.
Bonafini S1, Antoniazzi F2, Maffeis C2, Minuz P3, Fava C3.

Omega-3 polyunsatured fatty acids (ω-3 PUFA) are essential nutrients mainly derived from fish and seafood but present also in vegetables such as nuts and seed-oils.........
Îê. Õîòèòå ïîãîâîðèòü î ÒÅÎÐÅÒÈ×ÅÑÊÎÉ ÷àñòè ïðèìåíåíèÿ îìåãà-3, ãîòîâ ïîääåðæàòü, òåì áîëåå î òàêîé èçâåñòíîé ïðîáëåìå íà íàøåì êîíòèíåíòå, êàê áîëåçíü Àëüöãåéìåðà.

âîò òîæå åñòü ñòàòüÿ íàïèñàííàÿ, âàìè ëþáèìûìè èòàëüÿíñêèìè ó÷åííûìè (õîòÿ ÿ áîëüùå äîâåðÿþ èçðàèëüñêèì è àìåðèêàíñêèì):

Polyunsaturated omega-3 fatty acids are increasingly proposed as dietary supplements able to reduce the risk of development or progression of the Alzheimer's disease (AD). To date, the molecular mechanism through which these lipids act has not been yet univocally identified. In this work, we investigate whether omega-3 fatty acids could interfere with the fate of the Alzheimer-related amyloid peptide by tuning the microstructural and dynamical properties of the neuronal membrane. To this aim, the influence of the omega-3 lipid, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine [22:6(cis)PC] on the biophysical properties of lipid bilayers, and on their interaction with the amyloid peptide fragment Aβ(25-35) has been investigated by Electron Spin Resonance (ESR), using spin-labeled phospholipids. The results show that the peptide selectively interacts with bilayers enriched in cholesterol (Chol) and sphingomyelin (SM). [22:6(cis)PC] enhances the Aβ(25-35)/membrane interaction, favoring a deeper internalization of the peptide among the lipid acyl chains and, consequently, hindering its pathogenic self-aggregation.

Ìû âèäèì ÷òî îìåãà-3 æèðû ïðåïÿòñòâóþò ïàòîëîãè÷åñêîé ñàìîàããðåãàöèè àìèëîäíîãî ïåïòèäà, êîòîðûé ÿâëÿåòñÿ îäíèì èç ïðåäïîëàãàåìûõ ó÷àñòíèêîâ òðèããåðà DA :

Insight into the Inhibition Effect of Acidulated Serum Albumin on Amyloid β-Protein Fibrillogenesis and Cytotoxicity

Langmuir, 2014, 30 (32), pp 9789–9796

DOI: 10.1021/la5025197

Publication Date (Web): August 1, 2014

Copyright © 2014 American Chemical Society

Alzheimer’s disease (AD) is the most prevalent form of dementia, and aggregation of amyloid β-proteins (Aβ) into soluble oligomers and fibrils has been implicated in the pathogenesis of AD. Herein we developed acidulated serum albumin for the inhibition of Aβ42 fibrillogenesis. Bovine serum albumin (BSA) was modified with diglycolic anhydride, leading to the coupling of 14.5 more negative charges (carboxyl groups) on average on each protein surface. The acidulated BSA (A-BSA) was characterized and confirmed to keep the tertiary structure and stability of BSA. Extensive biophysical and biological analyses showed that A-BSA significantly inhibited Aβ42 fibrillogenesis and mitigated amyloid cytotoxicity. As compared to the Aβ42-treated group (cell viability, 50%), the cell viability increased to 88% by the addition of equimolar A-BSA. The inhibitory effect was remarkably higher than that of BSA at the same concentration. On the basis of the experimental findings, a mechanistic model was proposed. The model considers that Aβ42 is bound to the A-BSA surface by hydrophobic interactions, but the widely distributed negative charges on the A-BSA surface give rise to electrostatic repulsions to the bound Aβ42 that is also negatively charged. The two well-balanced opposite forces make Aβ42 adopt extended conformations instead of the β-sheet structure that is necessary for the on-pathway fibrillogenesis, even when the protein is released off the surface. Thus, A-BSA greatly slows down the fibrillation and changes the fibrillogenesis pathway, leading to the formation of less toxic aggregates. The findings and the mechanistic model offer new insights into the development of more potent inhibitors of Aβ fibrillogenesis and cytotoxicity.

1. Ìîæíî äîëãî ðàññêàçûâàòü î äîñòîèíñòâàõ îìåãà-3 æèðîâ. ÍÎ âû óõîäèòå îò âàæíîñòè ïðîáëåìû, íà êîòîðóþ ÿ óêàçàë, ÷òî íå ïðèåìëåìî äîêòîðó íåãàòèâíî âûñêàçûâàòüñÿ òàì, ãäå íàø ñ âàìè êîëëåãà, ïî âñåé âèäèìîñòè, íå ïîíèìàåò â ñèëó îòñóòñòâèÿ çíàíèé â ýòîé îáëàñòè.
2. Ïî ïîâîäó "ãèïîòåç" î ñâîéñòâàõ îìåãà-3...
Èòàê, ïåðâîå - Èíôîðìàöèÿ îá ýòèõ FA èçâåñòíà äîâîëüíî òàêè äàâíî è ìíîãî÷èñëåííûå èññëåäîâàíèÿ ãîâîðÿò íå î ãèïîòåòè÷åñêèõ ñâîéñòâàõ îìåãà-3, à î äîñòàòî÷íî ðåàëüíûõ äîêàçàííûõ ñâîéñòâàõ FA â òîì ÷èñëå è î çàìåùåíèÿ â íåêîòîðûõ ñëó÷àÿõ àðàõèäîíîâîé êèñëîòû â ìåìáðàíàõ êëåòîê [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - òóò ìîæíî ïîñìîòðåòü áîëåå ïîäðîáíóþ èíôîðìàöèþ (The American Journal of Clinical Nutrition).
3. Èçó÷àòü íóæíî, òîëüêî äëÿ òîãî ÷òîáû ãðàìîòíî ó÷àñòâîâàòü â òàêîãî ðîäà äèñêóññèè, à íå âûðàæàòü íåïðîôåññèîíàëüíîå "î çíàíèè ðåáåíêîì ÷òî åìó ïîëåçíî, à ÷òî íåò" Ïëþñ íå çíàíèå ïðåäìåòà èñêëþ÷àåò âîçìîæíîñòü äàâàòü ñîâåòû òèïà
Öèòàòà:
Ñîîáùåíèå îò doctor101 Ïîñìîòðåòü ñîîáùåíèå
ïîñêîëüêó áàäû íå ÿâëÿþòñÿ ëå÷åáíûìè ïðåïàðàòàìè-âñå ïî âàøåìó óñìîòðåíèþ
, ò.ê. ïðè íå êîòîðûõ ñîñòîÿíèÿõ íå ðåêîìåíäóåòñÿ ïðèíèìàòü îìåãà-3 â îáû÷íîé äîçèðîâêå (ò.å. íóæåí ñîâåò ñåìåéíîãî âðà÷à)


Ñ óâàæåíèåì
  #12  
Ñòàðûé 06.10.2016, 21:30
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,706
Ïîáëàãîäàðèëè 33,384 ðàç(à) çà 31,729 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
íèêàêèõ òåîðåòè÷åñêèõ ðàññóæäåíèé ìíå íå íóæíî, åñëè ó Âàñ åñòü ðåêîìåíäàöèè êàíàäñêèõ (èçðàèëüñêèõ/àìåðèêàíñêèõ) ïåäèàòðîâ, ÷òî äåòÿì íåîáõîäèìà îìåãà-3 äëÿ ïðîôèëàêòèêè Àëüöãåéìåðà - óêàæèòå ññûëêó, åñëè íåò - äàëüíåéøèé ðàçãîâîð íå ïîëó÷èòñÿ
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
  #13  
Ñòàðûé 07.10.2016, 16:59
DrGreen1 DrGreen1 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 28.09.2016
Ãîðîä: Mtl, Canada
Ñîîáùåíèé: 41
Ïîáëàãîäàðèëè 14 ðàç(à) çà 14 ñîîáùåíèé
DrGreen1 *
Öèòàòà:
Ñîîáùåíèå îò Dr.Vad Ïîñìîòðåòü ñîîáùåíèå
íèêàêèõ òåîðåòè÷åñêèõ ðàññóæäåíèé ìíå íå íóæíî, åñëè ó Âàñ åñòü ðåêîìåíäàöèè êàíàäñêèõ (èçðàèëüñêèõ/àìåðèêàíñêèõ) ïåäèàòðîâ, ÷òî äåòÿì íåîáõîäèìà îìåãà-3 äëÿ ïðîôèëàêòèêè Àëüöãåéìåðà - óêàæèòå ññûëêó, åñëè íåò - äàëüíåéøèé ðàçãîâîð íå ïîëó÷èòñÿ
Êîëëåãà, ÿ î÷åíü èçâèíÿþñü, íî ó ìåíÿ åñòü ñîìíåíèÿ, ÷òî âû âîîáùå ÷èòàåòå ìîè ìåññåäæè...
1-å åñëè âû âíèìàòåëüíî ïðî÷òåòå ìîé ïîèíò, òî âû íàéäåòå îòâåò íà áîëüøèíñòâî âîïðîñîâ.
2-å Ìîãëè áû âû âñïîìíèòü íà÷àëî íàøåé äèñêóññèè? ß ëè÷íî âàì äîêàçàë íåïðîôåññèîíàëüíûé îòâåò äîêòîðà â òåìå, î êîòîðîé îí ìàëî çíàåò.
3-å Óêàæèòå, ïëèç, ãäå ÿ ëè÷íî ðåêîìåíäóþ îìåãà-3 äåòÿì äëÿ ïðîôèëàêòèêè áîëåçíè Àëüöãåéìåðà??? Ýòîò âîïðîñ ïîñòàâèë ìåíÿ â òóïèê.... ó ìåíÿ ïîÿâèëîñü æåëàíèå ðàññêàçàòü âàì îá ýòîé áîëåçíè.
4-å Êàê âû ñ÷èòàåòå âèòàìèíû ÿâëÿþòñÿ ëåêàðñòâåííûìè ïðåïàðàòàìè ñ òî÷êè çðåíèÿ äîêàçàòåëüíîé ìåäèöèíû?
5-å Ñ÷èòàåòå ëè âû ÷òî íåêîìïåòåíòíûé äîêòîð â ñôåðå ãåìàòîëîãèè, ìîæåò ðåêîìåíäîâàòü íàïðèìåð ïðåïàðàòû æåëåçà, ññûëàÿñü íà òî ÷òî ýòî âñåãî ëèøü "ìèíåðàëüíûå äîáàâêè" è èõ ìîæíî ïðèíèìàòü êàê çàõî÷åòñÿ?

ß áû î÷åíü âàñ ïîïðîñèë îòâåòèòü õîòÿ áû íà ïàðó ìîèõ âîïðîñîâ. ß î÷åíü ïðîøó âàñ èçáåãàòü óëüòèìàòèâíîé ôîðìû îáùåíèÿ, ò.ê. ýòî íåïðîôåññèîíàëüíî è íåýòè÷íî.

P.S. íî åñëè âäðóã âàì âñå òàêè ïîíàäîáèòüñÿ äîçèðîâêà è ðåêîìåíäàöèè àìåðèêàíñêèõ äîêòîðîâ òî âîò ññûëêà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
  #14  
Ñòàðûé 07.10.2016, 17:33
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,706
Ïîáëàãîäàðèëè 33,384 ðàç(à) çà 31,729 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñîãëàñíî Âàøåé ññûëêå â áîëüøèíñòâå ñëó÷àåâ äåòÿì îìåãà-3 ðåêîìåíäóåòñÿ âñå æå èç ïðîäóêòîâ ïèòàíèÿ, à íå êàïñóë ñ äîçîé äëÿ âçðîñëûõ. Ìíå íå íóæíî íè÷åãî ðàññêàçûâàòü çà ìåäèöèíó íà ýòîì ôîðóìå, òàê êàê êàê è Âû ñâîáîäíî ÷èòàþ-ïîíèìàþ íà ìåæäóíàðîäíîì ÿçûêå ìåäèöèíû è åñòü áèáëèîòå÷íûé äîñòóï ê ïîñëåäíèì ïóáëèêàöèÿì ìèðîâûõ îïèíèîí ëèäåðîâ (ñ óäîâîëüñòâèåì ïðî÷òó è Âàøå ìíåíèå ïî Àëüöãåéìåðó, åñëè Âàñ òàêæå ñ÷èòàþò îïèíèîí ëèäåðîì â äàííîì âîïðîñå). Ëè÷íî Âû ìíå ïîêà íè÷åãî íå äîêàçàëè è äàæå íå ïîêàçàëè, î ÷åì Âàñ ïðîñèë â ñîîáøåíèè íîìåð 6. È âñòóïèë ñ Âàìè â áåñåäó èñêëþ÷èòåëüíî íà ïðàâàõ ìîäåðàòîðà ýòîãî ôîðóìà, èáî Âû íåîäíîêðàòíî áåçîñíîâàòåëüíî óòâåðæäàåòå î íèçêîì óðîâíå çíàíèé íàøåãî êîëëåãè, íè ñåêóíäû íå çàäóìûâàÿñü î òîì, íàñêîëüêî ýòî "íåïðîôåññèîíàëüíî è íåýòè÷íî". Íà÷íèòå ñ ñåáÿ, åùå ðàç ïî÷èòàéòå ïðàâèëà ôîðóìà ñ êîòîðûìè Âû ñîãëàñèëèñü ïðè ðåãèñòðàöèè. Îïÿòü æå íà ïðàâàõ ìîäåðàòîðà, çàêðûâàþ ýòó òåìó, èáî ñ÷èòàþ Âàøå ó÷àñòèå â íåé â äàííîì òîíå òîæå íåäîïóñòèìûì.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Çàêðûòàÿ òåìà



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 14:55.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.